Skip to main content

Psoriasis News

A recent meta-analysis highlighted several biologics that were associated with higher short-term and long-term PASI 75, PASI 90, and PASI 100 response rates.
Findings from a recent study showed an NK1 receptor antagonist may be an effective, new option for patients with psoriatic pruritus.
Results from a small retrospective study suggest adding apremilast to biologic therapy may be a safe and effective option for biologic fatigue among patients with psoriasis.
In a recent study that assessed the impact of metabolic conditions on health care costs and treatment outcomes for biologics and apremilast, the researchers found patients with psoriasis and metabolic conditions had higher rates of switching and discontinuation.
Findings from a recent study showed a biologic was still safe and effective among patients with psoriasis and metabolic syndrome.
A recent nationwide population-based cohort study investigated the impact of body weight variability on the risk of developing psoriasis.
Findings from a recent study suggest monitoring circulating drug levels of ustekinumab may help develop treatment strategies for patients with psoriasis.
Researchers investigated whether patients with psoriasis and a history of malignancy could effectively be treated with biologics or apremilast without recurrence or cancer progression.
In a recent study, researchers investigated the association between psoriasis and mortality risk, and whether this association was mediated by comorbidities, such as smoking and cardiovascular disease.
A phase 3, multicenter, randomized, controlled trial compared the efficacy of guselkumab with secukinumab for achieving PASI 90 after 48 weeks of treatment.
Back to Top